Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
Sponsor: Santa Chiara Hospital
Summary
The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice
Official title: Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Therapy (Alone or in Combination) or Radiotherapy on the Primary Tumor in Combination With Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Multicenter Observational Study of Patients Undergoing Treatment in Clinical Practice in Italian Hospitals
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
3000
Start Date
2016-12-16
Completion Date
2028-12
Last Updated
2024-06-25
Healthy Volunteers
Not specified
Interventions
Docetaxel
6 courses of docetaxel 75 mg/sqm iv
Apalutamide Oral Tablet
240 mg /daily orally
Enzalutamide Oral Tablet
600 mg /daily orally
Abiraterone acetate tablets
1000 mg /daily orally
Darolutamide Oral Tablet
600 mg/daily orally
radiotherapy
radical radiotherapy on primary tumor
Triptorelin
3,75 mg im/4 w
Locations (3)
Azienda Ospedaliera San Luigi
Orbassano, Torino, Italy
Istituto Oncologico Veneto
Padova, Italy
Santa Chiara Hospital
Trento, Italy